Kornimate/medical-research-clean huggingface dataset:
a computerised test for assessing the early reading skills

Conditions: Learning Disorders

Summary: this study was to develop a computerised test with an adapted peripheral to assess the emerging literacy knowledge of children with mobility difficulties. the software was implemented using a game-like design controllable by a peripheral device without needing fine movements.

conventional tests for assessing the early reading skills of preschool children on school entry are not accessible to children with mobility limitations. this paper presents a game-like computerised test featuring an appealing scenario that is accessible to these children. it was developed on a platform that creates 2d vector graphics and contains three phases of interactive content accessible through an adapted peripheral. conventional tests were also used to validate the effectiveness of the game. the two types of tests had the same degree of predictive power when completed by thirty three preschool children without mobility impairment.

Eligibility criteria:
inclusion criteria: * g1 and g2: preschool children; no motor difficulties and normal school performance. * g3: with moderate mobility impairment; similar cognitive ages and notions of writing to the participants of groups g1 and g2; children between seven and seventeen years old. exclusion criteria: * g1 and g2: children who often miss classes; children between four and seven years. * g3: no moderate mobility impairment

Keywords: early reading skills
pharmacodynamics, pharmacokinetics, efficacy and safety of balugrastim in pediatric patients with solid tumors

Conditions: Solid Tumors

Summary: the primary objective of this study is to find the optimal dose of balugrastim by characterizing its pharmacokinetics (pk), and by comparing the pharmacodynamics (pd) of balugrastim to filgrastim in children receiving chemotherapy.


Eligibility criteria:
inclusion criteria: 1. histological or cytologically-confirmed solid tumor in a patient for whom the study chemotherapy regimen \[vincristine plus ifosfamide plus doxorubicin plus etoposide (vide), vincristine plus doxorubicin plus cyclophosphamide alternating with ifosfamide plus etoposide (vdc/ie), ifosfamide plus vincristine plus actinomycin d (iva) or ifosfamide plus vincristine plus adriamycin (ivad)\] is considered an appropriate treatment. 2. minimum body weight of 15 kg 3. life expectancy of at least 3 months with appropriate therapy 4. female or male children and adolescents aged 2 to 17 years 5. written informed consent provided by parent(s)/legal representative(s) of the pediatric patient and patient's assent if appropriate at the time of screening. 6. fertile patients (male or female) must use highly reliable contraceptive measures. 7. female patients who have attained menarche must have a negative urine pregnancy test at the screening visit. 8. white blood cell (wbc) count \>2.5\*10\^9/l, anc ≥1.5\*10\^9/l, and platelet count ≥100\*10\^9/l (at screening and prior to chemotherapy) exclusion criteria: 1. primary myeloid disorders 2. prior radiation therapy within 4 weeks of randomization into this study. 3. previous exposure to filgrastim, pegfilgrastim, lenograstim or other g-csf less than 6 months before randomization. 4. known hypersensitivity to filgrastim, pegfilgrastim, lenograstim or any balugrastim excipients 5. pregnancy or breastfeeding (if a patient becomes pregnant during the study she will be withdrawn from the study). 6. major surgery, serious infection, within 3 weeks before first administration of study drug, serious trauma or compound medical procedure within the 4 weeks prior to the first study drug dose. 7. subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical exams, ecg, laboratory tests or imaging.

Keywords: solid tumors balugrastim
study to analyze the surgical site infections in a group of patients who were randomly applied a negative pressure therapy dressing versus conventional dressing

Conditions: Surgical Site Infection; Complication,Postoperative; Surgical Wound Infection; Surgical Complication

Summary: surgical site complications generate a series of consequences that prolong hospital stay, increase interventions and procedures, and consequently considerably increase healthcare costs. hence, the importance of studying measures to reduce these complications and the most feared of them is surgical site infection. the objective of the study is to analyze the complications of the surgical site in a group of participante with risk factors for developing them after undergone abdominal surgery in the period described.

all non-consecutive participants operated on in a hospital were included, both those who, based on a protocol prepared by the investigators unit, were classified as having no risk of developing complications, low risk or high risk. partfipants classified as low and high risk, after their consent to participate in the study, entered to form part of it. this participanta were classified before surgery according to the risk factors of themselves and of the procedure, and those at risk were randomized to treatment with a negative pressure therapy dressing or no treatment, and a cure was performed with a conventional dressing. the participants classified as not at risk of complications were not included in the study. in this way the investigators tried to analyze if the intervention with the negative pressure therapy dressing reduced the complications of the surgical site.the primary objective was to analyze the reduction of surgical site infections in participants treated with negative pressure therapy compared to those treated with conventional dressing. as secondary objectives the investigators proposed to measure other complications in both groups and the hospital stay.

Eligibility criteria:
inclusion criteria: * patients with risk factors for developing surgical site complications * undergo abdominal surgery * consent of the patient to participate in the study exclusion criteria: * non-consent of the patient to participate in the study * patients without risk of developing surgical site complications

Keywords: surgical site infections prophylaxis negative pressure wound therapy abdominal surgery
effect of therapeutic ultrasound versus anti-inflammatory drugs in the treatment of trigger finger

Conditions: Trigger Finger

Summary: to determine the effect of us on pain intensity in tf patients 2) to determine the effect of us on number of daily finger triggering in tf patients.

trigger finger (t.f) is a disorder characterized by snapping or locking of a finger. painful popping or clicking sound is elicited by flexion and extension of the involved digit . it is a multifactorial disease. the common mechanism of triggering is that there is a mismatch of diameter between flexors tendons and the annular pulley (retinacular sheath) of the finger. some studies found inflammatory cells as a part of the pathology, hence anti-inflammatory drugs are the first line of treatment . therapeutic ultrasound (us) is a form of acoustic energy which is often used in physical therapy. when us enters the body, it can affect the cells and tissues through thermal and non-thermal mechanisms. while a thermal mechanism has a direct heating effect which promotes anti-inflammatory response with increase blood flow, evidence indicates, however, that non thermal mechanisms are thought to play a primary role in producing a therapeutically significant biological effect (i.e. the stimulation of tissue regeneration) . so my question is in t.f patients does therapeutic ultrasound decrease pain more than anti-inflammatory drugs?

Eligibility criteria:
inclusion criteria: 1 - patients will be included to this study if they are trigger finger patients ( clinically evaluated and refereed by orthopedist). exclusion criteria: 1 - complete locked finger. 2-ages below 18 y. 3-patients with any other hand pathology .

Keywords: trigger finger therapeutic ultrasound
clinical assessment of a multifocal contact lens for people who use reading glasses only

Conditions: Presbyopia

Summary: the purpose of this trial is to evaluate the use of multifocal contact lenses in people who use reading glasses only.


Eligibility criteria:
inclusion criteria: * is between 40 and 48 years of age (inclusive). * has read and signed the informed consent. * is willing and able to follow instructions and maintain the appointment schedule. * wears reading spectacles for close work. * other protocol-defined inclusion/exclusion criteria may apply. exclusion criteria: * eye injury or surgery within twelve weeks of enrollment. * evidence of systemic or ocular abnormality, infection, or disease likely to affect successful wear of contact lenses or use of accessory solutions. * currently enrolled in a clinical trial. * has worn contact lenses previously. * other protocol-defined inclusion/exclusion criteria may apply.
evaluation of hoarding behaviour and eating disorders among holocaust survivors and their descendants

Conditions: Hoarding Disorder

Summary: "hoarding "is a common behavior among holocaust survivors and is related to the traumatic events they have experienced, and we assume that storage behavior and eating disorders are related to future generations of holocaust survivors.


Eligibility criteria:
inclusion criteria: 1. jewish holocaust survivors living in germany and israel who have expressed their written and written consent to participate in monitoring and testing, and who are able to answer the research questionnaires. • their direct offspring and their children (second and third generation) 2. the control population - non-jewish subjects who are not the descendants of holocaust survivors living in germany who have expressed their written and oral consent to participate in monitoring and testing and who are able to answer the research questionnaires and whose parents were not imprisoned in the camps second. exclusion criteria: * (participants who do not agree to participate (did not sign informed consent form * respondents who are unable to answer interviewer questions * non-jewish subjects whose parents were in camps (ie prisoner camps, labor camps, etc.) during the second war.
milk plus exercise: a novel strategy to treat diabetes.

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to investigate whether combining interval training with skim milk supplementation will result in improved glucose control and markers of cardiovascular health in people with type 2 diabetes. participants will complete supervised interval training three times a week over a 12 week training period while consuming skim-milk, whey/casein protein drink, or a placebo beverage that does not contain any calories or vitamins/minerals immediately and 1 hour after each training session. after twelve weeks participants will repeat baseline tests to examine any effects of the intervention on their glucose control, fitness, blood vessel function, body composition, and blood markers of inflammation.


Eligibility criteria:
inclusion criteria: * aged between 40 and 75. * diagnosed with type 2 diabetes for more than 6 months. * on stable medication for the last 6 months exclusion criteria: * type 2 diabetes controlled with exogenous insulin * uncontrolled hypertension (blood pressure \>160/90 mmhg) * history of heart disease, myocardial infarction or stroke * any other contraindications to exercise
impact of dha/oat on metabolic health in gestational diabetes mellitus

Conditions: Gestational Diabetes Mellitus in Pregnancy

Summary: the randomized controlled trial (rct) recruits pregnant women with de novo diagnosis of gestational diabetes. women bearing a singleton pregnancy are randomized into four arms: dha, oat, oat plus dha, and placebo. the primary outcomes are cord blood leptin concentration in the newborns and maternal fasting glucose levels at 8 weeks post-intervention.

dha is a long-chain fatty acid that has been shown to increase insulin sensitivity in basic science studies. some studies have reported that oat (β-glucan) intake in patients with type 2 diabetes may improve glycaemic control. evidence is emerging that gut microbiota may play an important role in energy homeostasis and glucose metabolism. this rct aims to test the hypothesis that dha and/or oat intake may improve glycemic control in women with gestational diabetes mellitus (gdm), and may impact metabolic health in fetuses/infants as indicated by cord blood leptin level. changes in microbiota may be linked to these effects. growing evidence suggests that epigenetic changes may occur during fetal development in response to an adverse in utero environment, and this may "program" the risk of metabolic syndrome and type 2 diabetes in adulthood. gdm's offspring are programmed to be at substantially elevated risk of metabolic syndrome and type 2 diabetes in adulthood. we will explore whether the intervention may affect epigenetic profile in placental dna in gdm. pregnant women bearing a singleton fetus without any evidence of malformation and with a de novo diagnosis of gdm at 22-28 weeks of gestation will be randomized into four arms: dha, oat, oat plus dha, and placebo. we will collect maternal blood and stool specimens on recruitment and 8-weeks post-intervention, cord blood and placenta specimens at delivery. the primary outcomes are cord blood leptin concentration in the baby, and fasting blood glucose at the 8 weeks post-intervention in the mother.

Eligibility criteria:
inclusion criteria: 1. han nationality 2. 20-45 years old 3. singleton pregnancy 4. natural conception 5. the pregnant women with de novo diagnosis of gestational diabetes mellitus during 22-28 weeks of pregnancy exclusion criteria: 1. pregnant woman or the biological father has diabetes mellitus (type i or ii) 2. the woman has severe diseases or life threatening conditions such as hiv, cancer, renal failure 3. the fetus has known congenital malformation or genetic defects 4. in-vitro fertilization 5. active hepatitis 6. tuberculosis 7. syphilis 8. drug abuser 9. multiple pregnancy

Keywords: gestational diabetes mellitus oat docosahexaenoic acid glycemic control intestinal flora newborn leptin
thermogenic properties of zantrex-3

Conditions: Obesity

Summary: background: zantrex-3® is a popular dietary supplement for weight control, which consists of a combination of yerba mate, guarana, caffeine and damiana. the combination has previously been shown to decrease gastric emptying and its weight controlling effects may be related to increased satiety and thermogenesis. objective: to investigate the effect of zantrex-3® on energy expenditure, hemodynamic factors and subjective appetite sensations. design: twenty-three men (bmi: 23.9±3.2 kg/m2, mean±sd) participated in a randomized, double-blind, placebo-controlled crossover study. the zantrex-3® compound contained 365 mg xantines (caffeine and caffeine-like stimulants), yerba mate, guarana and damiana. the thermogenic effect was measured for 3 hours post-intake. blood pressure (bp), heart rate (hr) and appetite ratings were assessed every half hour.


Eligibility criteria:
inclusion criteria: * healthy, * bmi: 23-30 kg/m2, * weight stable (within +/- 3 kg) two months prior to study inclusion, * non-smoking, * nonathletic (\< 10 h hard physical activity), \*the subjects followed a normal danish habitual diet with rare use of hot spices exclusion criteria: * change in smoking status, * daily or frequent use of medication, * suffering from metabolic diseases, * suffering from psychiatric diseases, * suffering from any other clinical condition, which would make the subject unfit to participate in the study, * use of dietary supplements or frequent use of medication * blood pressure above 160/90 mmhg

Keywords: energy expenditure appetite bioactive herbal compounds blood pressure
the effectiveness of the somatic intervention 'dance-walk' on body awareness, vitality, and mental health in adults seeking mental health support: a randomized controlled trial

Conditions: Healthy; Psychological Distress; Stress; Depression Disorders; Anxiety; Well-being; Mental Health; Body Awareness; Vitality

Summary: the goal of this clinical trial is to learn if a movement program called "dance-walk" can improve body awareness, energy levels, and mental health in adults seeking mental health support. the main questions it aims to answer are: does dance-walk help people feel more connected to their bodies? does dance-walk increase people's energy and vitality? does dance-walk improve mental health by reducing depression, anxiety, and stress? researchers will compare people who do dance-walk right away to people who wait to do the program later to see if dance-walk works to improve mental health. participants will: fill out online surveys about their mood, energy levels, and body awareness at the start of the study be randomly placed into one of two groups - one group will start dance-walk right away, the other will wait if in the first group, attend 4 weekly dance-walk sessions that combine movement, dance, and walking fill out the same surveys again after the 4-week program if in the waiting group, get to do the dance-walk program after the first group finishes each dance-walk session will focus on helping people tune into their body feelings and use movement to manage emotions and stress. the program is designed to help people feel more energetic and improve their overall mental well-being.


Eligibility criteria:
inclusion criteria: * age 18 years or older * seeking to improve emotional well-being or mental health * able to participate in light physical activity (walking and gentle movement) * able to read and understand lithuanian language * willing to attend 4 weekly group sessions * able to complete online questionnaires * willing to be randomly assigned to either immediate intervention or waitlist group * able to provide informed consent exclusion criteria: * under 18 years of age * current severe mental health crisis requiring immediate professional intervention * physical limitations that prevent participation in walking or gentle movement activities * unable to commit to attending 4 weekly sessions * currently participating in another research study involving mental health interventions * unable to access internet for completing online questionnaires

Keywords: mental health depression anxiety stress psychological distress emotional well-being somatic intervention body-mind intervention mind-body practice embodied practice body awareness interoception vitality subjective vitality positive mental health well-being adults help-seeking adults randomized controlled trial rct waitlist control autonomic nervous system emotion regulation stress reduction mindfulness self-awareness
clinical trial to evaluate the safety and efficacy of im19 car-t cells in patients with relapsed and refractory (r/r) b-cell acute lymphoblastic leukemia

Conditions: Leukemia

Summary: this is a open-label to assess the efficacy and safety of im19 car-t cells in r/r b-cell acute lymphoblastic leukemia.


Eligibility criteria:
inclusion criteria: * relapsed or refractory b-all, defined as：1）not chieving a cr after 1 cycle of standard chemotherapy for relapsed leukemia. 2）any relapse after hsct and must be ≥ 6 months from hsct at the time of im19 car-t cells infusion. 3）primary refractory as defined by not achieving a cr after 2 cycles of a standard chemotherapy regimen. * patients with ph+ all are eligible if they are intolerant to or have failed two lines of tki ± chemotherapy ；ph + all patients with t315i mutation are not required to receive at least two tki ± chemotherapy in the absence of effective tki therapy. * morphological evidence of disease in bone marrow (at least 5% blasts). * aged 3 to 70 years. * estimated life expectancy \>3 months. * ecog performance status of 0 or 1(age ≥ 16 years) or lansky (age \< 16 years). * women of childbearing age who had a negative blood pregnancy test before the start of the trial and agreed to take effective contraceptive measures during the trial period until the last follow-up; male subjects with fertility partners agreed to take effective contraceptive measures during the trial period until the last follow-up. * adequate organ function. * volunteer to participate in this trial and sign on the informed consent. exclusion criteria: * subjects with lsolated extramedullary disease relapse. * subjects with burkitt's lymphoma. * subjects has obvious symptoms of central nervous system invasion and needs targeted treatment. * subjects has previously received gene product therapy. * subjects has graft-versus-host response（gvhd） and need to use immunosuppressants or gvhd ≥ grade 2 or being treated with anti gvhd or suffering from autoimmune diseases. * subjects has received chemotherapy or radiotherapy within 3 days before leukapheresis. * subjects received systemic steroids within 5 days prior to leukapheresis. * subjects received drugs that stimulated the production of hematopoietic cells in the bone marrow for 5 days prior to leucapheresis. * subjects has participated in other clinical studies within 1 month before screening or plan to participate in other drug clinical trials during this study. * subjects received allogeneic cell therapy within 6 weeks before leukapheresis. * subjects with history or presence of cns disorder. * subjects with hbv, hcv, hiv ,ebv,ecv or syphilis infection at the time of screening. * pregnant or lactating, or planning pregnancy within 180 days after the end of car-t cells infusion, or male patients whose partners plan pregnancy 180 days after their car-t cell infusion. * subjects with other tumors in the past 5 years. * within 14 days before enrollment, there were active or uncontrollable infections requiring systemic treatment.

Keywords: car-t b-cell acute lymphoblastic leukemia
stonewall treatment evaluation project

Conditions: Substance Abuse; HIV Infections

Summary: this treatment outcome evaluation of the stonewall project will recruit 150 participants to complete a face-to-face assessment visit at baseline, 3-month follow-up, and 6-month follow-up to examine treatment outcome with respect to hiv risk and substance use.

stonewall project clients who have initiated treatment within the past 60 days will be eligible for the outcome evaluation. 20% of clients are likely to be on parole or probation; these clients will be eligible to participate in the study. outcome measures that will be examined as part of the treatment outcome evaluation include: 1) self-reported substance use; 2) urine toxicology screening; and 3) sex risk taking.

Eligibility criteria:
inclusion criteria: - participants in the outcome evaluation must have initiated services at the stonewall project within the past 60 days. exclusion criteria: - inability to provide informed consent as judged by the co-pi's and study team.

Keywords: methamphetamine men who have sex with men hiv/aids
efficacy of peripheral magnetic stimulation compare to dry needling in myofascial pain syndrome

Conditions: Myofascial Pain Syndrome

Summary: compare efficiency between repetitive peripheral magnetic stimulation and dry needling in patient with upper trapezius myofascial pain syndrome.


Eligibility criteria:
inclusion criteria: * patients with myofascial pain syndrome at unilateral upper trapezius muscle and had pain score (visual analog scale) at least 4 exclusion criteria: * patients with signs and/or symptoms of neurological deficit * patients with history of cervical hernia, cervical radiculopathy, cervical myelopathy, fibromyalgia, whiplash spondylosis and cervical spinal stenosis. * patients who received physical therapy/injection/surgery at neck or pain area in last 6 months. * patients with abnormal coagulopathy and/or currently use anticoagulant medicine. * patients with cardiac device. * patients with history of aneurysm clip procedure, stent-coils procedure or cochlear implant surgery. * pregnancy